<DOC>
	<DOCNO>NCT01049061</DOCNO>
	<brief_summary>MORAb-003 intravenously administer Japanese patient folate receptor-alpha express solid tumor week 4 week 1 cycle order investigate dose-limiting toxicity estimate maximum tolerate dose .</brief_summary>
	<brief_title>A Study MORAb-003 Patients With Solid Tumor</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion ; 1 . Japanese male female age &gt; or=20 &lt; 80 year obtain informed consent 2 . Patient histologically cytologically diagnose solid tumor 3 . Patient FRαpositive confirm immunohistochemistry ( IHC ) ( except ovarian cancer FRαpositive frequently report ) 4 . Patients folatereceptor alpha express solid tumor responsive resistant standard therapy appropriate treatment 5 . Performance Status ( PS ) 0 1 Eastern Cooperative Oncology Group（ECOG）criteria Exclusion criteria 1 . Brain metastasis present clinical symptom require medical treatment 2 . Serious systemic infection require medical treatment 3 . History hypersensitivity protein formulation include monoclonal antibody 4 . With active malignancy ( except carcinoma situ ) 5 . With large volume pleural effusion ascites require drainage</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>FRα</keyword>
</DOC>